Oncolys BioPharma Inc. (TYO:4588)

Japan flag Japan · Delayed Price · Currency is JPY
2,988.00
+128.00 (4.48%)
Apr 20, 2026, 1:50 PM JST
Market Cap83.72B +331.2%
Revenue (ttm)28.55M -9.0%
Net Income-2.06B
EPS-82.55
Shares Out29.27M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume195,000
Average Volume1,200,245
Open2,859.00
Previous Close2,860.00
Day's Range2,782.00 - 3,015.00
52-Week Range515.00 - 3,415.00
Beta1.04
RSI61.52
Earnings DateMay 8, 2026

About Oncolys BioPharma

Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranucl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 42
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4588
Full Company Profile

Financial Performance

In 2024, Oncolys BioPharma's revenue was 31.38 million, a decrease of -50.21% compared to the previous year's 63.04 million. Losses were -1.68 billion, -13.09% less than in 2023.

Financial Statements